Your browser is no longer supported. Please, upgrade your browser.
Settings
CRL [NYSE]
Charles River Laboratories International, Inc.
IndexS&P 500 P/E54.25 EPS (ttm)7.37 Insider Own1.00% Shs Outstand49.98M Perf Week3.59%
Market Cap19.93B Forward P/E34.87 EPS next Y11.46 Insider Trans-26.09% Shs Float49.50M Perf Month9.17%
Income375.10M PEG3.29 EPS next Q2.38 Inst Own97.00% Short Float1.30% Perf Quarter19.36%
Sales3.04B P/S6.55 EPS this Y41.90% Inst Trans0.02% Short Ratio1.05 Perf Half Y58.03%
Book/sh43.70 P/B9.14 EPS next Y15.23% ROA6.90% Target Price375.25 Perf Year102.47%
Cash/sh9.35 P/C42.72 EPS next 5Y16.50% ROE18.90% 52W Range195.48 - 397.61 Perf YTD59.94%
Dividend- P/FCF41.57 EPS past 5Y17.90% ROI8.60% 52W High0.51% Beta1.14
Dividend %- Quick Ratio1.50 Sales past 5Y16.50% Gross Margin37.10% 52W Low104.43% ATR6.38
Employees18400 Current Ratio1.80 Sales Q/Q16.60% Oper. Margin15.20% RSI (14)73.07 Volatility1.64% 1.65%
OptionableYes Debt/Eq1.01 EPS Q/Q18.60% Profit Margin12.30% Rel Volume0.38 Prev Close392.75
ShortableYes LT Debt/Eq1.01 EarningsAug 04 BMO Payout0.00% Avg Volume614.17K Price399.62
Recom1.80 SMA204.42% SMA5011.26% SMA20036.05% Volume230,318 Change1.75%
Dec-16-20Downgrade Citigroup Buy → Neutral $270 → $250
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Oct-18-19Downgrade BofA/Merrill Buy → Neutral $150
Jun-10-19Initiated SVB Leerink Outperform $155
Apr-30-19Resumed Evercore ISI Outperform $160
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Jul-28-21 03:03PM  
Jul-13-21 10:06AM  
08:30AM  
Jul-08-21 11:10AM  
Jul-06-21 02:31AM  
Jul-02-21 07:45PM  
Jun-30-21 09:46AM  
Jun-29-21 07:00AM  
Jun-23-21 10:44AM  
Jun-22-21 12:00PM  
Jun-10-21 08:00AM  
Jun-07-21 08:00AM  
08:00AM  
Jun-06-21 03:55AM  
May-28-21 08:00AM  
May-26-21 04:30PM  
08:05AM  
May-25-21 01:15PM  
May-17-21 01:16PM  
07:00AM  
May-10-21 06:37PM  
04:54PM  
May-07-21 03:18AM  
May-05-21 07:00PM  
May-04-21 03:31PM  
08:35AM  
07:00AM  
Apr-23-21 04:25PM  
Apr-16-21 10:45AM  
Apr-13-21 08:30AM  
Apr-06-21 04:43PM  
08:00AM  
Apr-04-21 05:16AM  
Mar-31-21 07:00AM  
Mar-29-21 04:19PM  
04:15PM  
Mar-23-21 04:30PM  
Mar-09-21 08:00AM  
Mar-08-21 11:11AM  
09:15AM  
08:30AM  
Mar-05-21 04:51AM  
Feb-25-21 08:00AM  
Feb-24-21 05:20AM  
Feb-18-21 01:15PM  
08:52AM  
Feb-17-21 04:00PM  
07:35AM  
07:08AM  
07:06AM  
Feb-10-21 12:31PM  
Jan-29-21 12:10PM  
Jan-28-21 08:00AM  
Jan-21-21 11:57PM  
Jan-20-21 08:30AM  
Jan-15-21 12:57PM  
Jan-14-21 08:00AM  
Jan-11-21 08:00AM  
Jan-06-21 04:03PM  
Jan-04-21 07:00AM  
Dec-25-20 02:44PM  
Dec-23-20 12:34AM  
Dec-21-20 01:42AM  
Dec-16-20 12:16PM  
Dec-09-20 08:00AM  
Nov-27-20 12:43AM  
Nov-20-20 03:07PM  
Nov-19-20 12:45PM  
Nov-12-20 08:00AM  
Nov-09-20 08:30AM  
Nov-05-20 09:15AM  
Nov-03-20 12:45PM  
Nov-01-20 08:20AM  
Oct-30-20 04:31AM  
Oct-29-20 09:00PM  
07:00AM  
Oct-28-20 12:26PM  
Oct-27-20 06:03PM  
Oct-26-20 06:53AM  
Oct-22-20 12:34PM  
12:10PM  
Oct-18-20 09:00PM  
Oct-17-20 12:19AM  
Oct-16-20 09:15AM  
Oct-13-20 08:30AM  
Oct-07-20 12:45PM  
Sep-26-20 09:51AM  
Sep-23-20 11:49AM  
Sep-21-20 02:52PM  
Sep-15-20 04:03PM  
03:11PM  
02:25PM  
11:36AM  
Sep-13-20 08:00PM  
08:00PM  
Sep-09-20 09:35AM  
Sep-08-20 08:30AM  
Aug-31-20 08:59AM  
Aug-28-20 11:20AM  
Aug-07-20 02:00AM  
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 04Option Exercise144.951,527221,3395,757Jun 07 06:23 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 04Sale335.241,527511,9064,230Jun 07 06:23 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 03Option Exercise101.4780081,1755,030Jun 04 09:34 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerJun 03Sale329.76800263,8094,230Jun 04 09:34 AM
FOSTER JAMES CChairman, President and CEOJun 01Option Exercise179.669,5771,720,604224,376Jun 03 12:48 PM
FOSTER JAMES CChairman, President and CEOJun 01Sale332.239,5773,181,749214,799Jun 03 12:48 PM
MASSARO GEORGEDirectorMay 11Sale320.06371118,7435,355May 12 04:45 PM
FOSTER JAMES CChairman, President and CEOMay 07Sale343.177,5002,573,770216,072May 10 05:13 PM
MASSARO GEORGEDirectorMay 06Sale336.963,3701,135,5615,371May 07 01:23 PM
Smith David RossCorporate Executive VP & CFOMay 04Option Exercise144.673,305478,13418,167May 06 01:21 PM
Smith David RossCorporate Executive VP & CFOMay 04Sale340.013,3051,123,71814,862May 06 01:21 PM
Smith David RossCorporate Executive VP & CFOApr 22Option Exercise109.343,845420,41218,707Apr 26 01:09 PM
Smith David RossCorporate Executive VP & CFOApr 22Sale330.003,8451,268,85014,862Apr 26 01:09 PM
Smith David RossCorporate Executive VP & CFOApr 15Sale320.002,000640,00014,862Apr 16 03:23 PM
Girshick BirgitCorporate Executive VPApr 06Option Exercise113.7918,3112,083,69535,469Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 06Sale302.6118,3115,541,10429,060Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 05Option Exercise88.0599987,96230,059Apr 07 11:26 AM
Girshick BirgitCorporate Executive VPApr 05Sale298.00999297,70229,060Apr 07 11:26 AM
MILNE GEORGE M JRDirectorMar 01Option Exercise52.293,530184,58431,947Mar 02 04:47 PM
Barbo William DCorporate Executive VP & CCOMar 01Option Exercise88.053,493307,5597,311Mar 02 04:37 PM
Smith David RossCorporate Executive VP & CFOMar 01Option Exercise88.054,366384,42621,228Mar 02 04:39 PM
Barbo William DCorporate Executive VP & CCOMar 01Sale290.431,157336,02816,975Mar 02 04:37 PM
Barbo William DCorporate Executive VP & CCOMar 01Sale290.103,4931,013,3123,818Mar 02 04:37 PM
Smith David RossCorporate Executive VP & CFOMar 01Sale290.124,3661,266,64716,862Mar 02 04:39 PM
MILNE GEORGE M JRDirectorMar 01Sale290.013,5301,023,73028,417Mar 02 04:47 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 25Option Exercise88.052,750242,13819,996Feb 26 04:51 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopFeb 25Sale281.708,7352,460,61511,261Feb 26 04:51 PM
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise88.0524,0092,113,992245,160Feb 25 04:23 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale284.7524,0096,836,607221,151Feb 25 04:23 PM
CHUBB STEPHEN DDirectorFeb 23Option Exercise52.293,530184,58441,187Feb 24 11:02 AM
FOSTER JAMES CChairman, President and CEOFeb 23Option Exercise109.3420,2952,219,055243,656Feb 24 11:10 AM
CHUBB STEPHEN DDirectorFeb 23Sale281.66658185,33040,529Feb 24 11:02 AM
FOSTER JAMES CChairman, President and CEOFeb 23Sale279.8020,2955,678,578223,361Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 22Option Exercise144.6717,4362,522,466244,605Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 22Sale282.9817,4364,934,118227,169Feb 24 11:10 AM
Girshick BirgitCorporate Executive VPFeb 19Option Exercise73.701,675123,44831,680Feb 23 11:41 AM
Girshick BirgitCorporate Executive VPFeb 19Sale293.921,675492,31130,005Feb 23 11:41 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerFeb 19Sale290.99410119,3054,198Feb 23 11:32 AM
Smith David RossCorporate Executive VP & CFOFeb 19Sale290.638,6562,515,6860Feb 23 11:16 AM
FOSTER JAMES CChairman, President and CEOFeb 11Sale285.0230,0008,550,556227,169Feb 16 11:58 AM
Smith David RossCorporate Executive VP & CFOJan 04Sale248.765,0001,243,78815,767Jan 05 05:21 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Option Exercise123.736,739833,84118,095Nov 05 11:46 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Sale250.286,7391,686,62711,356Nov 05 11:46 AM
Barbo William DCorporate Executive VP & CCONov 03Sale236.292,150508,0159,821Nov 05 03:51 PM
WALLMAN RICHARD FDirectorNov 02Buy233.246,0501,411,1046,050Nov 03 01:21 PM
WALLMAN RICHARD FDirectorNov 02Buy232.961,150267,90231,715Nov 03 01:21 PM
FOSTER JAMES CChairman, President and CEONov 02Sale232.3822,0005,112,267186,777Nov 03 04:05 PM
MASSARO GEORGEDirectorSep 14Sale219.911,943427,2849,441Sep 15 05:47 PM
Girshick BirgitCorporate Executive VPAug 20Sale213.51933199,20522,852Aug 21 10:48 AM
CHUBB STEPHEN DDirectorAug 18Sale217.651,000217,65137,657Aug 19 02:48 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Option Exercise111.413,441383,3535,855Aug 10 03:20 PM
Smith David RossCorporate Executive VP & CFOAug 07Option Exercise144.673,304477,99024,071Aug 10 04:18 PM
Smith David RossCorporate Executive VP & CFOAug 07Sale216.543,304715,44420,767Aug 10 04:18 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Sale216.603,456748,5552,399Aug 10 03:20 PM
Kochevar Deborah TurnerDirectorAug 07Sale216.242,319501,4676,728Aug 11 10:39 AM
FOSTER JAMES CChairman, President and CEOAug 07Sale217.4924,0005,219,771210,777Aug 10 04:25 PM